华森制药(002907.SZ)：克唑替尼胶囊获得药品注册证书

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received the drug registration certificate from the National Medical Products Administration for Crizotinib capsules, which have been on the Chinese market since 2013 and included in medical insurance since 2018, demonstrating over ten years of clinical application experience [1] Group 1 - Crizotinib capsules are primarily used for treating patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and ROS1-positive advanced NSCLC [1] - As a first-line treatment option, Crizotinib capsules provide over seven years of overall survival benefits for patients with advanced ALK/ROS1-positive NSCLC [1] - Crizotinib is the world's first targeted drug for ALK and the first-generation ALK tyrosine kinase inhibitor (ALK-TKI), targeting ALK and ROS1 to inhibit tumor cell proliferation and survival through a multi-target mechanism [1]